Download PDF
Semin Plast Surg 2014; 28(02): 087-090
DOI: 10.1055/s-0034-1376259
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Beta-Blockers as Therapy for Infantile Hemangiomas

Harrison P. Nguyen
1   Baylor College of Medicine, Houston, Texas
,
Brent B. Pickrell
1   Baylor College of Medicine, Houston, Texas
,
Teresa S. Wright
2   Department of Dermatology, Texas Children's Hospital, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
31 May 2014 (online)

    Permissions and Reprints

Abstract

Infantile hemangiomas (IH) are common benign vascular tumors seen in children. Although the majority will improve spontaneously without treatment, a small subset will require therapy due to a variety of complications. Less than a decade ago, propranolol replaced corticosteroids as first-line treatment for most IH and it has proven to be a relatively safe, effective therapy. After initiation of propranolol, most hemangiomas show evidence of significant improvement relatively rapidly, often within days. Although propranolol is generally felt to have a more limited side-effect profile than systemic corticosteroids, its use has been infrequently associated with adverse events, including sleep disturbances, acrocyanosis, hypotension, bradycardia, respiratory events, and hypoglycemia. Rarely, hypoglycemic seizures have been reported, usually occurring in the setting of prolonged fasting.

Keywords

infantile hemangiomas - pediatric tumors - β-blocker - propranolol - timolol
 

  • References

  • 1 Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48 (4) 477-493 , quiz 494–496
    CrossrefPubMedGoogle Scholar
  • 2 Mazereeuw-Hautier J, Hoeger PH, Benlahrech S , et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010; 157 (2) 340-342
    CrossrefPubMedGoogle Scholar
  • 3 Shah S, Frieden IJ. Treatment of infantile hemangiomas with beta-blockers: a review. Skin Therapy Lett 2013; 18 (6) 5-7
    PubMedGoogle Scholar
  • 4 Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25 (2) 168-173
    CrossrefPubMedGoogle Scholar
  • 5 Blei F, Walter J, Orlow SJ, Marchuk DA. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 1998; 134 (6) 718-722
    CrossrefPubMedGoogle Scholar
  • 6 Haggstrom AN, Drolet BA, Baselga E , et al; Hemangioma Investigator Group. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150 (3) 291-294
    CrossrefPubMedGoogle Scholar
  • 7 Chang LC, Haggstrom AN, Drolet BA , et al; Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122 (2) 360-367
    CrossrefPubMedGoogle Scholar
  • 8 Yu Y, Fuhr J, Boye E , et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006; 24 (6) 1605-1612
    CrossrefPubMedGoogle Scholar
  • 9 Barnés CM, Huang S, Kaipainen A , et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A 2005; 102 (52) 19097-19102
    CrossrefPubMedGoogle Scholar
  • 10 Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107 (6) 745-752
    CrossrefPubMedGoogle Scholar
  • 11 Walter JW, North PE, Waner M , et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002; 33 (3) 295-303
    CrossrefPubMedGoogle Scholar
  • 12 Razon MJ, Kräling BM, Mulliken JB, Bischoff J. Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 1998; 5 (2-3) 189-195
    CrossrefPubMedGoogle Scholar
  • 13 Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93 (6) 2357-2364
    CrossrefPubMedGoogle Scholar
  • 14 Ritter MR, Moreno SK, Dorrell MI , et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol 2003; 1 (4) 291-299
    CrossrefPubMedGoogle Scholar
  • 15 Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells in infantile hemangioma. Am J Pathol 2006; 168 (2) 621-628
    CrossrefPubMedGoogle Scholar
  • 16 Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136 (7) 905-914
    CrossrefPubMedGoogle Scholar
  • 17 Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol 2010; 146 (7) 767-774
    PubMedGoogle Scholar
  • 18 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24) 2649-2651
    CrossrefPubMedGoogle Scholar
  • 19 Sans V, de la Roque ED, Berge J , et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124 (3) e423-e431
    CrossrefPubMedGoogle Scholar
  • 20 Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg 2013; 131 (3) 601-613
    CrossrefPubMedGoogle Scholar
  • 21 Price CJ, Lattouf C, Baum B , et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011; 147 (12) 1371-1376
    CrossrefPubMedGoogle Scholar
  • 22 Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163 (2) 269-274
    CrossrefPubMedGoogle Scholar
  • 23 Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propanolol and infantile hemangiomas four years later:. a systematic review. Pediatr Dermatol 2013; 30 (2) 182-191
    CrossrefPubMedGoogle Scholar
  • 24 de Graaf M, Breur JM, Raphaël MF, Vos M, Breugem CC, Pasmans SG. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 2011; 65 (2) 320-327
    CrossrefPubMedGoogle Scholar
  • 25 Bagazgoitia L, Hernández-Martín A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol 2011; 28 (6) 658-662
    CrossrefPubMedGoogle Scholar
  • 26 Drolet BA, Frommelt PC, Chamlin SL , et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131 (1) 128-140
    CrossrefPubMedGoogle Scholar
  • 27 Raphaël MF, de Graaf M, Breugem CC, Pasmans SG, Breur JM. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol 2011; 65 (2) 420-421
    CrossrefPubMedGoogle Scholar
  • 28 Blanchet C, Nicollas R, Bigorre M, Amedro P, Mondain M. Management of infantile subglottic hemangioma: acebutolol or propranolol?. Int J Pediatr Otorhinolaryngol 2010; 74 (8) 959-961
    CrossrefPubMedGoogle Scholar
  • 29 Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol 2013; 168 (1) 222-224
    CrossrefPubMedGoogle Scholar
  • 30 Chakkittakandiyil A, Phillips R, Frieden IJ , et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29 (1) 28-31
    CrossrefPubMedGoogle Scholar